significantly more patients in the insulin pen group prepared and self-injected at least one dose of insulin compared with the vial and syringe group. Patients with newly diagnosed or existing ...

Insulin pumps and CGMS provide greater flexibility, improved blood sugar control, and better quality of life for children and ...

NovoPen ®, the first insulin pen injector, was introduced in 1985 ... as conventional insulin regimens employing syringes. The published evidence identified also showed that insulin ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30% ...

The trade show floor offers a firsthand look at how market trends shape current design and manufacturing innovations.

Embecta Corp (EMBC) reports a mixed quarter with revenue declines but strong growth in safety products and contract manufacturing, while focusing on debt reduction and strategic partnerships.

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Adjusted EBITDA margin increased to 37.2% from 25.2% in Q4 2024, driven by cost reductions and operational improvements. Management's tone shifted positively, highlighting stronger-than-expected ...

Q1 2025 Earnings Call Transcript February 6, 2025 Embecta Corp. beats earnings expectations. Reported EPS is $0.65, ...